Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03699527 · ClinicalTrials.gov registry record
Medical Cannabis Registry and Pharmacology
A clinical trial, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- 119
- Enrollment target
NCT03699527: Completed study, sponsored by Children's Hospital of Philadelphia.
NCT03699527 is a clinical trial that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 119 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03699527 has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- 119 participants
- Enrollment target
Study Summary
The overall goals of this research is to describe the 1) natural history of current use and disposition of medical cannabis products including Cannabidiol (CBD) products, being administered to children as standard of care for the treatment of Autism Spectrum Disorder (ASD), 2) understand the pharmacokinetic and pharmacodynamics of medical cannabis products and 3) provide educational feedback on what is learned to families and care providers to provide evidenced based dosing guidance for these products to the pediatric community.
Primary Outcome
The primary objective is to create a registry that will describe the natural history and landscape of medical cannabis and CBD use in the pediatric ASD population.
Interventions
- BEHAVIORAL Multiple questionnaires administered
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2018-07-15 |
| Est. Completion | 2020-01-15 |
What the finished NCT03699527 record still lists
NCT03699527 is an observational study that tracks outcomes without assigning an intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Multiple questionnaires administered is the first listed.
NCT03699527 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03699527 about?
NCT03699527 is a clinical study titled "Medical Cannabis Registry and Pharmacology". The overall goals of this research is to describe the 1) natural history of current use and disposition of medical cannabis products including Cannabidiol (CBD) products, being administered to children as standard of care for the treatment of Autism Spectrum Disorder (ASD), 2) understand the pharmac...
What is the current status of trial NCT03699527?
This trial is currently completed. The enrollment target is 119 participants. The study started on 2018-07-15. Estimated completion is 2020-01-15.
What interventions are being tested in trial NCT03699527?
The interventions under investigation include: Multiple questionnaires administered (BEHAVIORAL).
Who is sponsoring clinical trial NCT03699527?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI